Not provided
Not provided
Not provided
Not provided
No patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Russian Academy of Medical Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with COVID-19.
Fortelyzin® (the active substance Forteplase) is a recombinant non-immunogenic staphylokinase with high fibrinselective thrombolytic activity. In a multicentre, randomised clinical trial in patients with ST-segment elevation myocardial infarction (FRIDOM), non-immunogenic staphylokinase was administered as a single intravenous bolus of 15 mg in all patients, regardless of bodyweight, and showed similar high reperfusion patency and fewer minor bleeding events compared with tenecteplase, as well as the absence of neutralising IgGs. Results of the multicentre, randomised clinical trial in patients with an acute ischaemic stroke (FRIDA) suggested that the non-immunogenic staphylokinase administrated as a single intravenous bolus of 10 mg in all patients within the 4-5 h after the onset of symptoms is non-inferior to alteplase. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ between treatment groups (Gusev EI, Martynov MYu, Nikonov AA et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4-5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021; 20(9): 721-728).
Complex coagulation and hematologic abnormalities, including significantly elevated D-dimer and fibrin/fibrinogen values are the distinct features identified in severe SARS-CoV-2. In the list of antithrombotic therapy drugs in conjunction with anticoagulant and antiplatelet therapy in patients with COVID-19, published by Liverpool Drug Interactions Group, fibrinolytic therapy is also included.
So the main objectives of this study are to assess the tolerability, safety and efficacy of inhaled usage of fibrinolytic agent the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with COVID-19.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | Experimental | Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight. |
|
| Placebo control | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Recombinant nonimmunogenic staphylokinase | Drug | 15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin® |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or less | The efficacy is evaluated in terms of the number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or less | 28 days post randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or less | The efficacy is evaluated in terms of the number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or less | 14 days post randomization |
Not provided
Inclusion Criteria:
Men and women aged 18 and over
Clinical status according to the WHO scale - 6, 7, 8 and 9 points.
Verified respiratory infection COVID-19 by real-time PCR (quantitative)
Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:
Availability of signed and dated informed consent of the patient to participate in the study.
Exclusion Criteria:
Clinical status according to the WHO scale - 1, 2, 3, 4 and 5 points.
Increased risk of bleeding:
Lactation, pregnancy
Known hypersensitivity to Fortelyzin®.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sergey S. Markin, MD, PhD | LLC "SuperGene" | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City Clinical Hospital No.52 | Moscow | 123182 | Russia | |||
| N.V. Sklifosovsky Research Institute of Emergency Medicine |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34418399 | Result | Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, Yarovaya EB, Semenov AM, Archakov AI, Markin SS; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021 Sep;20(9):721-728. doi: 10.1016/S1474-4422(21)00210-6. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
At clinical centers, patients will be randomly distributed by the "envelope method" into two groups to receive Fortelyzin® or placebo.
The drugs will be administered after the signed informed consent. Fortelyzin® will be administered by inhalation of a dose of 15 mg.
Not provided
Not provided
Patients and study investigators will be blinded to subject treatment
| Placebo | Drug | 6 ml of 0.9% solution of NaCl for inhalation |
|
|
| Hospital length of stay | The efficacy is evaluated in terms of the hospital length of stay | 28 days post randomization |
| Number of ICU-free days | The efficacy is evaluated in terms of the number of ICU-free days | 28 days post randomization |
| Number of ventilation-free days | The efficacy is evaluated in terms of the number of ventilation-free days | 28 days post randomization |
| Number of oxygen support-free days | The efficacy is evaluated in terms of the number of oxygen support-free days | 28 days post randomization |
| SpO2 level | The efficacy is evaluated in terms of the SpO2 level | 7, 14 and 28 days post randomization |
| Moscow |
| 129090 |
| Russia |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |